<DOC>
	<DOCNO>NCT01376765</DOCNO>
	<brief_summary>This multi-center , randomize , double-blinded , placebo-controlled , outpatient study . Recombinant deltaTM S Protein Severe Acute Respiratory Syndrome ( SARS ) Vaccine With Without Aluminum Hydroxide Adjuvant ( Provided contract N01-AI-30023 , manufacture Protein Sciences Corporation ) , two dos , administer 28 day interval . 1 . S Protein Severe Acute Respiratory Syndrome ( SARS ) Vaccine without adjuvant : 5.0 , 15.0 45.0 mcg per 0.5 ml dose . 2 . S Protein SARS Adjuvanted Vaccine : 5.0 , 15.0 45.0 mcg per 0.5 ml dose . PLACEBO : diluents/placebo without vaccine ( Phosphate Buffer Saline ( PBS ) low phosphate concentration ) . Approximately 84 healthy male nonpregnant female subject 18 40 year age enrol .</brief_summary>
	<brief_title>Phase I Dose Escalation SARS-CoV Recombinant S Protein , With Without Adjuvant , Vaccine Study</brief_title>
	<detailed_description>This Phase 1 , multi-center , randomize , double-blinded , placebo-controlled , outpatient study healthy male nonpregnant female subject 18 40 year age , inclusive . Three dose cohort investigate safety , reactogenicity , immunogenicity Recombinant S protein Severe Acute Respiratory Syndrome ( SARS ) vaccine , without aluminum hydroxide adjuvant manufacture Protein Sciences Corporation , administer intramuscularly Days 0 28 dose 5 , 15 , 45 mcg ; control receive diluents/placebo without vaccine . Approximately 84 subject expect enrolled . All subject receive 2 dos assign treatment via IM injection approximately 28 day apart , follow assessment 6 , 12 , 15 , 18 , 21 24 month second dose .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Males nonpregnant female age 18 40 year , inclusive . Women childbearing potential ( surgically sterile via tubal ligation , bilateral oophorectomy hysterectomy postmenopausal &gt; /=1 year ) must agree practice adequate contraception 30day period vaccination 90 day second vaccination . Acceptable birth control method purpose study may include , limited , abstinence , monogamous relationship vasectomize partner , barrier method condom , diaphragm , spermicide , intrauterine device , license hormonal method . In good health , judge investigator determine vital sign [ temperature &lt; 38 degree C , heart rate &lt; /= 100 bpm &gt; 50 bpm , systolic blood pressure &lt; /= 140 mmHg &gt; 89 mmHg , diastolic blood pressure &lt; /= 90 mmHg &gt; /= 60 mm Hg , respiratory rate &gt; /= 12 breath per minute &lt; 17 breath per minute ( see toxicity table Section 9.1.2 ) ] , medical history target physical examination , indicate , base medical history . Screening laboratory value must within normal limit . These include blood hemoglobin , white blood cell ( WBC ) count , eosinophil , platelet , absolute eosinophil , neutrophil , lymphocyte cell count , creatinine , aspartate aminotransferase ( AST ) , alanine transaminase ( ALT ) , bilirubin ( total ) , glucose ( random ) , urinalysis ( proteinuria hematuria ) . See toxicity table Section 9.1.3.2 . Note : creatinine value low normal acceptable . Able understand comply plan study procedure . Willing available studyrequired procedure , visit call duration study . Provide write informed consent initiation study procedure available study visit . Negative IgG antibody S protein Severe Acute Respiratory Syndrome coronavirus ( SARSCoV ) measure ELISA . Negative antibody Human Immunodeficiency Virus ( HIV ) hepatitis C virus hepatitis B surface antigen . Negative IgG antibody S protein Severe Acute Respiratory Syndrome coronavirus ( SARSCoV ) measure ELISA . Negative antibody Human Immunodeficiency Virus ( HIV ) hepatitis C virus hepatitis B surface antigen . A known allergy component vaccine . A positive serum urine pregnancy test within 24 hr prior vaccination ( female childbearing potential define Inclusion Criterion 2 ) , woman plan become pregnant 30 day prior enter study 90 day final study vaccination , woman breastfeed . Immunosuppression result underlie illness treatment use anticancer chemotherapy radiation therapy ( cytotoxic ) within precede 36 month . An active neoplastic disease ( exclude nonmelanoma skin cancer prostate cancer stable absence therapy ) history hematologic malignancy . Nonactive neoplastic disease define neoplastic disease treatment neoplastic disease within past 5 year . A history autoimmune disease ( systemic lupus , rheumatoid arthritis , scleroderma , polyarteritis , thyroiditis , etc ) . Used immunosuppressive immunomodulatory drug &gt; 0.5 mg/kg/day &gt; /=20 mg total dose/day prednisone orally &gt; 800 mcg inhale beclomethasone 2 consecutive week within 6 month prior 1st vaccination . ( Nasal topical steroid allow . ) A know human immunodeficiency virus ( HIV ) infection , active hepatitis B , hepatitis C virus infection . A diagnosis schizophrenia , bipolar disease , major psychiatric diagnosis past 3 year . Hospitalized psychiatric illness , history suicide attempt , confinement danger self others past 3 year . Receiving psychiatric drug list below* . Subjects receive single antidepressant drug stable least 3 month prior enrollment , without decompensating symptom allow enrolled study . *aripiprazole , clozapine , ziprasidone , haloperidol , molindone , loxapine , thioridazine , thiothixene , pimozide , fluphenazine , risperidone , mesoridazine , quetiapine , trifluoperazine , trifluopromazine , chlorprothixene , chlorpromazine , perphenazine , olanzapine , carbamazepine , divalproex sodium , lithium carbonate , lithium citrate . A history receive immunoglobulin blood product within previous 3 month vaccination . Received plan receive live license vaccine within 4 week inactivate licensed vaccine within 2 week vaccination , An acute chronic medical condition , opinion investigator , would render vaccination unsafe would interfere evaluation response generally see healthy , normal subject . ( This include , limited , know cardiac disease , pulmonary disease , liver disease , renal disease , unstable progressive neurological disorder , diabetes mellitus , transplant recipient . ) A history severe reaction follow immunization vaccine . Received experimental agent ( vaccine , drug , biologic , device , blood product , medication ) within 1 month vaccination study expect receive experimental agent 24month study period . Any condition would , opinion investigator , place unacceptable risk injury , render unable meet requirement protocol , may interfere successful completion study . A history alcohol drug abuse previous 1 year ; example , daily excessive alcohol use frequent binge drinking determine investigator , chronic marijuana abuse illicit drug use . Plans travel outside North America time 1st vaccination 56 day follow first vaccination plan travel Southeast Asia entire study participation . Body temperature &gt; /=100.4 F ( &gt; /=38.0 C ) acute illness within 3 day vaccination ( subject may reschedule ) . Planned known exposure Himalayan palm civet , raccoon dog Southeast Asia , Chinese horseshoe bat , include bat ship Southeast Asia previously house Southeast Asian counterpart .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>SARS , coronavirus , vaccine , adjuvant , AlhydrogelÂ® , severe acute respiratory syndrome</keyword>
</DOC>